Abstracts tagged "Psoriasis and safety"

Abstract Number: 1503 • 2019 ACR/ARP Annual Meeting
Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials
Mark Genovese¹, Hideto Kameda ², Proton Rahman ³, Juan Cañete ⁴, Sandra Garces ⁵, Wen Xu ⁶, Matthew M. Hufford ⁵ and Bernard Combe ⁷, ¹Stanford University, Stanford, CA, ²Toho University, Tokyo, Japan, Tokyo, Japan, ³Memorial University, Newfoundland, NL, Canada, ⁴Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷CHU Montpellier, Montpellier University, Montpellier, France
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that specifically targets IL-17A. Pooled safety data from IXE studies in moderate-to-severe plaque psoriasis (PsO) and psoriatic…
Abstract Number: 1690 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate to Severe Psoriasis: 52-Week Results
Kristian Reich¹, Jennifer Soung², Melinda Gooderham³, Zuoshun Zhang⁴, Kristine Nograles⁴, Robert M. Day⁴, Laura Ferris⁵ and Mark Goodfield⁶, ¹SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany, ²Southern California Dermatology, Santa Ana, CA, ³SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada, ⁴Celgene Corporation, Summit, NJ, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Department of Dermatology, Leeds Centre for Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Psoriasis is a chronic systemic inflammatory disease often treated with conventional systemic and biologic drugs that may variously be ineffective, be inaccessible, or pose…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].